IL4R and chronic rhinosinusitis: Dupilumab, a fully human monoclonal antibody directed against the interleukin-4 receptor α (IL-4Rα), is currently approved for the treatment of moderate-to-severe AD across a broad age spectrum, including adults, adolescents, and children as young as 6 months, as well as for asthma with an eosinophilic phenotype or oral corticosteroid dependence [7], and chronic rhinosinusitis with nasal polyposis [8].